This company develops host-directed antiviral biologics using a proprietary platform for the rapid design of broad-spectrum drug candidates. Their platform has demonstrated preclinical efficacy against 21 different viruses across nine virus families. They aim to provide effective treatments for existing viral diseases and preparedness against future pandemic threats.
Funding
$11.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
The majority of the 220 viruses known to infect humans lack approved antiviral treatments, leaving a significant gap in addressing both existing and emerging viral threats. Current antiviral drugs are often virus-specific, limiting their effectiveness against a broad range of viral infections and potential pandemic outbreaks.
Solution
Kimer Med is developing a family of broad-spectrum antiviral therapeutics that target viral double-stranded RNA (dsRNA), a common feature across virtually all viruses. Inspired by the DRACO antiviral discovery, Kimer Med's biologics bind to long strands of viral dsRNA, inhibiting viral infection and replication. This approach offers a potential "one drug for many bugs" solution, providing a critical line of defense against multiple viral threats, including Dengue, Zika, HSV-2, and Influenza. By targeting a common viral component, Kimer Med's antivirals can be deployed both before and after exposure, offering immediate relief and protection.
Target Audience
The primary target audience includes healthcare providers, public health organizations, and individuals seeking protection against a wide range of viral infections and potential pandemics.
Features
- Broad-spectrum antiviral activity against 21 human viruses, including Dengue, Zika, HSV-2, and Influenza
- Utilizes large molecule biologics that bind to viral dsRNA
- Mechanism of action inhibits viral infection and replication
- Potential for both therapeutic and prophylactic use
- R&D conducted in a fully equipped PC-2 laboratory
- Confirmation of lab results by independent laboratories